Literature DB >> 3098689

Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal level.

S Ferrini, L Moretta, G Pantaleo, A Moretta.   

Abstract

Lymphokine-activated killer (LAK) activity was first analyzed on PBL populations fractionated on the basis of the expression of T11 or T3 antigen. LAK cell precursors were found to be present in both T11+ and T11- populations, but only in the T3- cell fraction. The generation of LAK activity in highly purified T3- populations of PBL was not accompanied by expression of T3 antigen during a 5-day culture period. LAK activity was next analyzed at the level of limiting dilution clonal microcultures. T11+T3- and T11+T3+ cells, cloned under optimal culture conditions, gave a frequency of proliferating cells of approximately 1 cell in 1.25 for T11+T3+ and 1 cell in 10 for T11+T3- cells. Clones were screened for their ability to lyse fresh ovarian carcinoma cells and K562 target cells. The majority of LAK clones were derived from the T11+T3- cells; moreover, most of the clones derived from these cells displayed LAK activity. Clones displaying LAK activity lysed a panel of fresh or cultured tumor target cells, but failed to lyse PHA-activated lymphoblasts. Surface marker analysis indicated that all the clones had maintained the original T11/T3 phenotype. Whereas 2 T3+ selected LAK clones expressed the T8+T4- phenotype, only 1 out of 9 T3- clones was T8+T4-, all the others lacking both T4 and T8 antigens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3098689     DOI: 10.1002/ijc.2910390105

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.

Authors:  A S Chong; A Aleksijevic; P Scuderi; E M Hersh; W J Grimes
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.

Authors:  M Sensi; L Grazioli; M Rodolfo; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.

Authors:  D G Morris; H F Pross
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

4.  Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.

Authors:  A K Ghosh; M Mellor; J Prendiville; N Thatcher
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

5.  Human cytolytic cell clones lacking surface expression of T cell receptor alpha/beta or gamma/delta. Evidence that surface structures other than CD3 or CD2 molecules are required for signal transduction.

Authors:  G Pantaleo; M R Zocchi; S Ferrini; A Poggi; G Tambussi; C Bottino; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

6.  Establishment of mouse lymphokine-activated killer cell clones and their properties.

Authors:  K Kato; N Sato; T Tanabe; H Yagita; T Agatsuma; Y Hashimoto
Journal:  Jpn J Cancer Res       Date:  1991-04

7.  Two populations of mouse lymphokine-activated killer cells separated by use of soybean agglutinin.

Authors:  M Takano; T Okada; T Maruyama; K Harada; Y Imai; T Osawa
Journal:  Jpn J Cancer Res       Date:  1989-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.